Emerging reports indicate that mammalian cells have key NAD+ ase in the form of CD38 and that the manipulation of NAD+ metabolism may represent a plausible strategy to ameliorate obesity, metabolic syndrome and type 2 diabetes. The gene discussed is CD38; the disease is obesity due to melanocortin 4 receptor deficiency.